Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
US11046695B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11046695-B2 |
| Application number | US-201615775319-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2016 |
| Priority date | Nov 11, 2015 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
There is described herein use of a compound of formula (I) below to make cyclic peptides.
Opening claim text (preview).
The invention claimed is: 1. A process for preparing a cyclic peptide of formula (II): wherein: —C(O)-L-Z— is selected from the group consisting of: comprising the following steps: (i) cyclizing head-to-tail a linear peptide of formula (IIa): wherein: R d is tert-butyloxycarbonyl or 9-fluorenylmethoxycarbonyl; and —C(O)-L-Z′ is selected from the group consisting of: in the presence of 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one, to provide a cyclic peptide of formula (IIb): wherein: R d is tert-butyloxycarbonyl or 9-fluorenylmethoxycarbonyl; and —C(O)-L-Z— is selected from the group consisting of: (ii) deprotecting the cyclic peptide of formula (IIb) above in the presence of piperidine and N-methyl-2-pyrrolidone, to provide the cyclic peptide of formula (II) above. 2. The process of claim 1 , wherein —C(O)-L-Z— is: 3. The process of claim 1 , wherein —C(O)-L-Z— is: 4. The process of claim 1 , wherein —C(O)-L-Z— is: 5. The process of claim 1 , wherein —C(O)-L-Z— is: 6. The process of claim 1 , wherein —C(O)-L-Z— is:
Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
for pancreatic disorders, e.g. pancreatic enzymes · CPC title
by covalent attachment of amino acids or peptide residues · CPC title
Ortho-condensed systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.